|
Gene: ANKRD50 |
Gene summary for ANKRD50 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ANKRD50 | Gene ID | 57182 |
Gene name | ankyrin repeat domain 50 | |
Gene Alias | ANKRD50 | |
Cytomap | 4q28.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q8TB46 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
57182 | ANKRD50 | LZE4T | Human | Esophagus | ESCC | 1.18e-05 | 2.19e-01 | 0.0811 |
57182 | ANKRD50 | LZE5T | Human | Esophagus | ESCC | 4.10e-02 | 5.35e-01 | 0.0514 |
57182 | ANKRD50 | LZE8T | Human | Esophagus | ESCC | 1.12e-06 | 2.40e-01 | 0.067 |
57182 | ANKRD50 | LZE24T | Human | Esophagus | ESCC | 4.09e-08 | 1.62e-01 | 0.0596 |
57182 | ANKRD50 | P1T-E | Human | Esophagus | ESCC | 1.53e-02 | 2.65e-01 | 0.0875 |
57182 | ANKRD50 | P2T-E | Human | Esophagus | ESCC | 3.01e-16 | 1.50e-01 | 0.1177 |
57182 | ANKRD50 | P4T-E | Human | Esophagus | ESCC | 1.01e-13 | 2.17e-01 | 0.1323 |
57182 | ANKRD50 | P5T-E | Human | Esophagus | ESCC | 2.34e-05 | -1.43e-04 | 0.1327 |
57182 | ANKRD50 | P8T-E | Human | Esophagus | ESCC | 3.50e-12 | 2.56e-01 | 0.0889 |
57182 | ANKRD50 | P9T-E | Human | Esophagus | ESCC | 3.04e-06 | 5.87e-02 | 0.1131 |
57182 | ANKRD50 | P10T-E | Human | Esophagus | ESCC | 1.39e-10 | 1.14e-01 | 0.116 |
57182 | ANKRD50 | P11T-E | Human | Esophagus | ESCC | 1.43e-02 | 1.77e-01 | 0.1426 |
57182 | ANKRD50 | P12T-E | Human | Esophagus | ESCC | 3.29e-19 | 4.77e-01 | 0.1122 |
57182 | ANKRD50 | P15T-E | Human | Esophagus | ESCC | 2.75e-15 | 2.79e-01 | 0.1149 |
57182 | ANKRD50 | P16T-E | Human | Esophagus | ESCC | 1.19e-06 | 7.61e-02 | 0.1153 |
57182 | ANKRD50 | P20T-E | Human | Esophagus | ESCC | 4.40e-07 | 6.07e-02 | 0.1124 |
57182 | ANKRD50 | P21T-E | Human | Esophagus | ESCC | 1.07e-08 | 8.52e-02 | 0.1617 |
57182 | ANKRD50 | P22T-E | Human | Esophagus | ESCC | 3.91e-25 | 3.51e-01 | 0.1236 |
57182 | ANKRD50 | P23T-E | Human | Esophagus | ESCC | 1.20e-07 | 1.67e-01 | 0.108 |
57182 | ANKRD50 | P24T-E | Human | Esophagus | ESCC | 2.75e-03 | 9.14e-03 | 0.1287 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001619715 | Esophagus | ESCC | endosomal transport | 168/8552 | 230/18723 | 2.28e-17 | 1.93e-15 | 168 |
GO:009887615 | Esophagus | ESCC | vesicle-mediated transport to the plasma membrane | 99/8552 | 136/18723 | 1.13e-10 | 3.39e-09 | 99 |
GO:00324565 | Esophagus | ESCC | endocytic recycling | 51/8552 | 73/18723 | 2.47e-05 | 2.10e-04 | 51 |
GO:00988768 | Prostate | BPH | vesicle-mediated transport to the plasma membrane | 43/3107 | 136/18723 | 1.11e-05 | 1.51e-04 | 43 |
GO:00161978 | Prostate | BPH | endosomal transport | 62/3107 | 230/18723 | 4.54e-05 | 4.77e-04 | 62 |
GO:00324563 | Prostate | BPH | endocytic recycling | 21/3107 | 73/18723 | 6.45e-03 | 2.91e-02 | 21 |
GO:009887613 | Prostate | Tumor | vesicle-mediated transport to the plasma membrane | 42/3246 | 136/18723 | 7.47e-05 | 7.84e-04 | 42 |
GO:001619713 | Prostate | Tumor | endosomal transport | 62/3246 | 230/18723 | 1.65e-04 | 1.47e-03 | 62 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANKRD50 | SNV | Missense_Mutation | rs373595841 | c.2581T>A | p.Leu861Met | p.L861M | Q9ULJ7 | protein_coding | tolerated(0.1) | possibly_damaging(0.571) | TCGA-HF-7132-01 | Stomach | stomach adenocarcinoma | Male | Unknown | I/II | Chemotherapy | fluorouracil | SD |
ANKRD50 | SNV | Missense_Mutation | c.4112N>A | p.Ser1371Asn | p.S1371N | Q9ULJ7 | protein_coding | tolerated_low_confidence(0.44) | benign(0) | TCGA-HU-A4GN-01 | Stomach | stomach adenocarcinoma | Male | <65 | I/II | Chemotherapy | mitomycin | PD | |
ANKRD50 | SNV | Missense_Mutation | c.4172N>G | p.Gln1391Arg | p.Q1391R | Q9ULJ7 | protein_coding | tolerated_low_confidence(0.49) | possibly_damaging(0.901) | TCGA-HU-A4H4-01 | Stomach | stomach adenocarcinoma | Female | <65 | I/II | Chemotherapy | ts-1 | CR | |
ANKRD50 | SNV | Missense_Mutation | novel | c.3946G>A | p.Ala1316Thr | p.A1316T | Q9ULJ7 | protein_coding | tolerated_low_confidence(0.59) | benign(0.003) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
ANKRD50 | SNV | Missense_Mutation | novel | c.1853C>A | p.Ala618Asp | p.A618D | Q9ULJ7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response | |
ANKRD50 | SNV | Missense_Mutation | novel | c.1262N>A | p.Cys421Tyr | p.C421Y | Q9ULJ7 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-VQ-A91E-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
ANKRD50 | SNV | Missense_Mutation | rs750924375 | c.932N>G | p.Asp311Gly | p.D311G | Q9ULJ7 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-VQ-A91U-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
ANKRD50 | SNV | Missense_Mutation | novel | c.481N>A | p.Cys161Ser | p.C161S | Q9ULJ7 | protein_coding | deleterious(0.02) | benign(0.258) | TCGA-ZQ-A9CR-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
ANKRD50 | deletion | Frame_Shift_Del | novel | c.2897delN | p.Leu966Ter | p.L966* | Q9ULJ7 | protein_coding | TCGA-BR-8368-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ANKRD50 | insertion | Frame_Shift_Ins | novel | c.596_597insGAAACTAGTT | p.Asn199LysfsTer7 | p.N199Kfs*7 | Q9ULJ7 | protein_coding | TCGA-E8-A436-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |